Auteurs
Analysis
UK
Racine
Analysis
UK
Exploration
Accueil
Racine
Racine

Serveur d'exploration sur les relations entre la France et l'Australie - Analysis (UK)

Index « Auteurs » - entrée « Valeria Santini »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Valeria Pensotti < Valeria Santini < Valeria Sorrentino  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 6.
Ident.Authors (with country if any)Title
001528 (2014) Pierre Fenaux [France] ; John F. Seymour [Australie] ; Valeria Santini [Italie] ; Lew Silverman [États-Unis] ; Steven Gore [États-Unis] ; Alan List [États-Unis] ; Guillermo Sanz [Espagne] ; Ghulam J. Mufti [Royaume-Uni] ; Eli Estey [États-Unis] ; Arlene S. Swern [États-Unis] ; C L Beach [États-Unis] ; Eva Hellstrom-Lindberg [Suède]Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study model.
001773 (2014) John F. Seymour [Australie] ; John M. Bennett [États-Unis] ; Alan F. List [États-Unis] ; Ghulam J. Mufti [Royaume-Uni] ; Steven D. Gore [États-Unis] ; Pierre Fenaux [France] ; Valeria Santini [Italie] ; Joel Hetzer [États-Unis] ; Stephen Songer [États-Unis] ; Barry S. Skikne [États-Unis] ; Charles L. Beach [États-Unis]Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes
002478 (2011) Lewis R. Silverman [États-Unis] ; Pierre Fenaux [France] ; Ghulam J. Mufti [Royaume-Uni] ; Valeria Santini [Italie] ; Eva Hellström-Lindberg [Suède] ; Norbert Gattermann [Allemagne] ; Guillermo Sanz [Espagne] ; Alan F. List [États-Unis] ; Steven D. Gore [États-Unis] ; John F. Seymour [Australie]Continued Azacitidine Therapy Beyond Time of First Response Improves Quality of Response in Patients With Higher-Risk Myelodysplastic Syndromes
002659 (2010) Valeria Santini [Italie] ; Pierre Fenaux [France] ; Ghulam J. Mufti [Royaume-Uni] ; Eva Hellström-Lindberg [Suède] ; Lewis R. Silverman [États-Unis] ; Alan List [États-Unis] ; Steven D. Gore [États-Unis] ; John F. Seymour [Australie] ; Jay Backstrom [États-Unis] ; Charles L. Beach [États-Unis]Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine
002826 (2010) John F. Seymour [Australie] ; Pierre Fenaux [France] ; Lewis R. Silverman [États-Unis] ; Ghulam J. Mufti [Royaume-Uni] ; Eva Hellström-Lindberg [Suède] ; Valeria Santini [Italie] ; Alan F. List [États-Unis] ; Steven D. Gore [États-Unis] ; Jay Backstrom [États-Unis] ; David Mckenzie [États-Unis] ; C. L. Beach [États-Unis]Effects of azacitidine compared with conventional care regimens in elderly (>75 years) patients with higher-risk myelodysplastic syndromes
002856 (2010) Pierre Fenaux [France, Royaume-Uni, Suède, Italie, Allemagne, Espagne, Australie, États-Unis] ; Ghulam J. Mufti ; Eva Hellstrom-Lindberg ; Valeria Santini ; Norbert Gattermann ; Ulrich Germing ; Guillermo Sanz ; Alan F. List ; Steven Gore ; John F. Seymour ; Hervé Dombret ; Jay Backstrom ; Linda Zimmerman ; David Mckenzie ; C. L. Beach ; Lewis R. SilvermanAzacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

List of associated KwdEn.i

Nombre de
documents		Descripteur
5Azacitidine
4Antineoplastic agent
4Cancerology
4Myelodysplastic syndrome
3Survival
3Therapeutic protocol
2Acute myelogenous leukemia
2Bone marrow
2Care
2Comparative study
2Elderly
2Human
2Risk factor
1Adverse events management
1Antimetabolites, Antineoplastic (therapeutic use)
1Azacitidine (therapeutic use)
1Azacitidine dose
1Azacitidine therapy
1Azacitidine treatment
1Azacitidine treatment cycles
1Baseline
1Blast
1Calgb
1Celgene corporation
1Clin oncol
1Clinical Trials, Phase III as Topic (methods)
1Clinical Trials, Phase III as Topic (standards)
1Concomitant
1Concomitant medications
1Constipation
1Conventional care regimens
1Cytarabine
1Disease progression
1Dose delays
1Dose reductions
1Dosing
1Drugs, Investigational (therapeutic use)
1Early treatment cycles
1Febrile neutropenia
1Gastrointestinal events
1Grade grade
1Hematologic
1Hematology
1High risk
1Humans
1John wiley sons santini
1Leukemia group
1Median
1Median duration
1Median durations
1Medication
1Multicenter Studies as Topic (methods)
1Multiple reports
1Myelodysplastic
1Myelodysplastic Syndromes (drug therapy)
1Myelodysplastic syndromes
1Nadir values
1Neutropenia
1Numeration
1Oncol
1Patient Selection
1Patients preselected
1Patients randomized
1Platelet
1Preselected
1Prognosis
1Prolonged
1Pyrexia
1Quality
1Randomized
1Randomized Controlled Trials as Topic (methods)
1Randomized Controlled Trials as Topic (standards)
1Regimen
1Research Design
1Response time
1Santini
1Standard of Care
1Study designs
1Subsequent cycles
1Syndrome
1Thrombocytopenia
1Tolerance
1Toxicity
1Treatment
1Treatment cycle
1Treatment efficiency

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/UK/Analysis

HfdIndexSelect -h $EXPLOR_AREA/Data/UK/Analysis/Author.i -k "Valeria Santini" 

HfdIndexSelect -h $EXPLOR_AREA/Data/UK/Analysis/Author.i  \
                -Sk "Valeria Santini" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/UK/Analysis/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    UK
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    Valeria Santini
}}
Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024